Ocular Therapeutix Inc
Closed
SectorHealthcare
8.93 2.64
Overview
Share price change
24h
Min
8.61
Max
8.93
Income | -24M -89M |
|---|---|
Sales | -2.5M 11M |
EPS | -0.4 |
Profit margin | -821.623 |
Employees | 325 |
EBITDA | -31M -92M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +170.11% upside |
Next Earnings | 4 sie 2026 |
|---|
Market Cap | -352M 1.8B |
|---|---|
Previous open | 6.29 |
Previous close | 8.93 |
Ocular Therapeutix Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Ocular Therapeutix Inc Forecast
Price Target
By TipRanks
170.11% upside
12 Months Forecast
Average 23.5 USD 170.11%
High 31 USD
Low 18 USD
Based on 7 Wall Street analysts offering 12 month price targets forOcular Therapeutix Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
